Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 10/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26968502 | 0.83 | ADORA3 (0.51) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL26968541 | 0.82 | ADORA3 (0.67) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL26968689 | 0.81 | ADORA3 (0.45) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL26968745 | 0.79 | ADORA3 (0.46) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL26968409 | 0.78 | ADORA3 (0.46) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL29108596 | 0.77 | ADORA3 (0.49) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL26968625 | 0.76 | ADORA3 (0.70) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL26968540 | 0.76 | ADORA3 (0.48) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL26968465 | 0.76 | ADORA3 (0.48) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL26968654 | 0.76 | ADORA3 (0.46) | ADORA3ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199679-A1 | ADENOSINE DERIVATIVE HAVING ANTAGONISTIC ACTION ON A2A AND A3 ADENOSINE RECEPTORS AND METHOD FOR PREPARING SAME | FUTURE MEDICINE CO., LTD. (KR) | 2024-06-20 | — | — | US | disclosed |
| EP-4296273-A1 | ADENOSINE DERIVATIVE HAVING ANTAGONISTIC ACTION ON A2A AND A3 ADENOSINE RECEPTORS AND METHOD FOR PREPARING SAME | Future Medicine Co., Ltd. (KR) | 2023-12-27 | — | — | EP | disclosed |
| WO-2022203427-A1 | ADENOSINE DERIVATIVE HAVING ANTAGONISTIC ACTION ON A2A AND A3 ADENOSINE RECEPTORS AND METHOD FOR PREPARING SAME | 퓨쳐메디신 주식회사 | 2022-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199679-A1 | ADENOSINE DERIVATIVE HAVING ANTAGONISTIC ACTION ON A2A AND A3 ADENOSINE RECEPTORS AND METHOD FOR PREPARING SAME | ADORA2A, ADORA3, ADORA2B | ADORA3 2/4885ADORA2A 1/4885ADORA2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.